For US Healthcare Professionals

container

form-title

Request a Meeting with An Alnylam Patient Education Liaison (PEL)

Requesting a meeting with an Alnylam Patient Education Liaison is quick and easy. Start by filling out the form below.

The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team. PELs do not provide medical care or advice. All diagnosis and treatment decisions should be made by you and your doctor.

Select the date and time that works best for you:

YOUR MEETING REQUEST HAS BEEN SUBMITTED

container

schedule-form

Current First Form Page
Schedule Calender Page
Complete

All fields are required, unless otherwise stated.

First Name

Last Name

Gender

Female

Male

Other/
Prefer Not to Answer

Street Address

City

State

Zip / Postal Code

Phone Number

(Optional)

OK to leave a voicemail

I would also like Alnylam to contact my healthcare provider to discuss AHP. I understand that the Alnylam representative will not discuss my medical information or personal information with my healthcare provider.

First Name (Healthcare Provider)

Last Name (Healthcare Provider)

Name of Medical Practice

Street Address (Healthcare Provider)

City (Healthcare Provider)

State (Healthcare Provider)

Zip / Postal Code (Healthcare Provider)

Phone Number (Healthcare Provider)

(Optional)

OK to leave a voicemail

Required Responses

I would like an Alnylam Patient Education Liaison to contact me with information about acute hepatic porphyria (AHP).

I understand that the Alnylam PEL is not providing me medical advice and is not part of my healthcare team.

By submitting this form, I agree to the Alnylam Privacy Policy, I am 18 years or older, a US resident, and consent to the processing of my personal data per the terms outlined in the Data Privacy Notification and Consent.

I understand that Alnylam will use reasonable technical and organizational measures to protect the information I share with the PEL and will not use or disclose it outside of the company.

Email already in use

Please press Cancel to enter another email address or press Update to receive an email that will allow you to update your preferences.

Update Cancel

IMPORTANT SAFETY INFORMATION

Do not use GIVLAARI if you have ever had a severe allergic reaction to GIVLAARI.

GIVLAARI can cause:

Severe allergic reaction
Tell your doctor or nurse right away if you experience any of the following signs or symptoms of a severe allergic reaction during treatment:
- Swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
- Breathing problems or wheezing
- Feeling dizzy or fainting
- Rash or hives
- Itching
If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.
Liver problems
Your doctor will check your liver function by doing blood tests:
- Before you start using GIVLAARI
- Once a month for the first 6 months of treatment
- And when they think it is needed
If these tests show abnormal results, your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.
Kidney problems
Your doctor will check how your kidneys are working while you are using GIVLAARI.
Injection site reactions
GIVLAARI is given as an injection under the skin (called a “subcutaneous injection”). Reactions to this injection may happen during treatment with GIVLAARI.

Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.
Increased blood homocysteine levels
GIVLAARI may cause increased levels of homocysteine (a type of amino acid) in your blood. Your doctor will check your homocysteine levels before and during treatment by doing blood tests. If your levels are increased, your doctor may check your folate, vitamins B12 and B6, and tell you to take a vitamin B6 supplement.

What are the common side effects of GIVLAARI?

The most common side effects of GIVLAARI are nausea and injection site reactions. These are not all the possible side effects of GIVLAARI. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

WHAT IS GIVLAARI^® (givosiran)?

GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.

For additional information about GIVLAARI, please see the full Prescribing Information.

Copyright © Alnylam Pharmaceuticals, Inc. All Rights Reserved. AMVUTTRA is a trademark of Alnylam Pharmaceuticals, Inc. ONPATTRO is a registered trademark of Alnylam Pharmaceuticals, Inc. OXLUMO is a registered trademark of Alnylam Pharmaceuticals, Inc. GIVLAARI is a registered trademark of Alnylam Pharmaceuticals, Inc. ONPATTRO, GIVLAARI, and OXLUMO are registered trademarks, and AMVUTTRA is a trademark of Alnylam Pharmaceuticals, Inc.

MB-USA-00022